Dr. Subhash Basu, professor emeritus of chemistry and biochemistry, will embark on a speaking tour of India on Tuesday to discuss his current research on potential new anti-cancer drugs. Basu will make his second appearance at the International Cancer Research Symposium on Dec. 19 in Calcutta when he gives a lecture titled “Probable New Therapeutic Drugs for Breast and Colon Cancers.” “The invitation to this symposium is very prestigious. Sixty people from all over the world are going to Calcutta,” he said. “I will tell them what our plan is for the delivery of these new anti-cancer drugs.” Basu’s lecture tour will also include an appearance at the Indian Science Congress on Jan. 4, where he will discuss the apoptotic, or cell-killing, effects of the drugs he is working with his collaborators to develop. “Our work is important, and we get an invitation every year to speak at these sorts of things,” he said. Basu said he and his research team have discovered five to six different new anti-cancer compounds that would be useful for treating colon and breast cancer patients. “These chemicals are quite toxic to biological cells and they kill cancer cells by enhancing apoptosis, or programmed cell death, in a very micro amount,” he said. Now that these cancer-killing compounds have been discovered, Basu said the main goal of his work is to determine ways to deliver the drugs into patients at the location of the cancer without harming the healthy cells around the cancerous ones. “Cancer cells normally die of necrosis – they make holes in themselves,” he said. “When apoptosis happens, the cell gets bigger and its DNA starts degrading until the cell cannot function.” Basu said about 50,000 women die of breast cancer in the United States each year, so his research could impact thousands of lives in the future. “Chemotherapy could be improved by our procedure by giving patients micro doses of drugs so they don’t kill the normal cells,” he said. “Thus, the success of these apoptotic chemicals as anti-cancer drugs depends on their proper delivery to the cancer sites.” To facilitate and fund his research in this area, Basu founded the Cancer Drug Delivery Research Foundation (CDDRF) in 2010, of which he serves as president. The foundation received its first major source of support when the University transferred all of Basu’s recoupment to CDDRF in May, he said. “All this recoupment was brought in by me from federal grants and other sources during my time at the University,” Basu said. “This foundation is tax-exempt and will help only for my research, so any patent money we get can go into the research as well.” Basu said his status as a permanently appointed emeritus professor gave him the freedom to move his lab from campus to a currently undetermined site near campus. “The University said I would have to give half of whatever I bring in to Notre Dame if I continue to work in a lab here,” he said. “It becomes cheaper for me to run my lab outside because I can use 100 percent of my money for research.” Since joining the faculty at Notre Dame in 1970, Basu has received major grants from the National Institutes of Health and the National Cancer Institute.
One point separates them from safety in what has developed into a fraught relegation battle, with every team from Hull, in 13th, downwards still in danger of the drop. Magath, who insists he will be reading German crime fiction to help calm his nerves over the coming days, has never been relegated in his 19-year managerial career. “I’m afraid for the club, not for my personal record. I have nothing to prove in my career,” he said. “I knew it was a difficult situation when I came here. I’m confident I can manage it. “I worry a little bit about the last matches but I’m confident. We can make it better on Saturday.” With Fulham’s Premier League survival hanging by a thread, Magath is wary of using the Greece striker at this stage of the season and will not be influenced by his price tag. “Kostas is part of our team now and he can play again this season,” Magath said. “I feel pressure to pick the best 11. It is not just black and white when you consider a player, you must think about how to get the best from him. “He’s a player who is very dangerous in the box. At the beginning, as we played, we weren’t coming into the box. “It was not the right situation for him. Now we are creating some chances and coming into the box. In the box he is very good. “Kostas wants to play and will help us. You never know if he has not played how he will realise his abilities in a game. “You can try in training sessions but it is not the same situations in training sessions as in games.” Magath accepts that only victories against Stoke at the Britannia Stadium on Saturday and against Crystal Palace at Craven Cottage eight days later will give Fulham a chance of staying in the top flight. Mitroglou is finally available to join the squad for Saturday’s Barclays Premier League clash at Stoke after almost two months out with a persistent knee problem. The £12milllion accusation on transfer deadline day has made just two appearances since his arrival in January. Felix Magath feels no pressure to pick Fulham’s record signing Kostas Mitroglou for the last two matches of the season. Press Association